137 Results for "

lacks

" in MedChemExpress (MCE) Product Catalog:
Products (137)

137 Results for "lacks" in MCE Product Catalog:

9
9 Publications Verification
Cat. No.: HY-P99045
CAS No.: 1796566-95-4
Synonyms: HRS7; hRS7

Target:  

ADC Antibodies TROP2

Research Areas:  

Cancer

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
loading...
    loading...
9
9 Publications Verification
Cat. No.: HY-100359
CAS No.: 307002-71-7
Purity:  99.71%
Target:  

MMP

Research Areas:  

Inflammation/Immunology Cancer

CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs . CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-18669
CAS No.: 100872-83-1
Target:  

HSP

Research Areas:  

Cancer

ML346 is an activator of Hsp70 expression and HSF-1 activity, with an EC50 of 4.6 μM for Hsp70. ML346 restores protein folding in conformational disease models, without significant cytotoxicity or lack of specificity. ML346 induces specific increases in genes and protein effectors of the heat shock response (HSR), including chaperones such as Hsp70, Hsp40, and Hsp27 .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P99029
CAS No.: 2169232-81-7
Synonyms: Hu5F9-G4

Target:  

CD47

Research Areas:  

Cancer

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-124593
CAS No.: 1256565-36-2
Purity:  99.89%
Synonyms: Emvododstat
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-137808
CAS No.: 108347-97-3
Purity:  94%
Synonyms: Succinyl-CoA sodium
Succinyl CoA (Succinyl-coenzyme A) sodium is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA sodium is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA sodium acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA sodium insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA sodium can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1122
CAS No.: 83602-39-5
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-106783
CAS No.: 86408-36-8
Purity:  99.82%
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Polymyxin B nonapeptide is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-106783A
CAS No.: 2220175-42-6
Purity:  99.79%
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Polymyxin B nonapeptide TFA is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide TFA is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136093A
CAS No.: 1422365-94-3
Purity:  99.88%
Synonyms: IM156; HL156A; HL271 acetate
Lixumistat (IM156) acetate is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat acetate strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat acetate exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12397
CAS No.: 156965-15-0
Purity:  99.23%
Target:  

VD/VDR

Research Areas:  

Endocrinology

ZK159222, a 25-carboxylic ester analogue of 1α,25-(OH)2D3, is a potent 1α,25-(OH)2D3 receptor (VDR) antagonist. The mechanism of ZK159222 antagonistic action is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. ZK159222 has a partial agonistic character .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136093B
CAS No.: 1422365-93-2
Synonyms: IM156 free base; HL156A free base; HL271 free base
Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136093
CAS No.: 1422365-52-3
Purity:  99.25%
Synonyms: HL271; IM156 hydrochloride; HL156A hydrochloride
Research Areas:  

Neurological Disease

Lixumistat (IM156) hydrochloride is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat hydrochloride strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat hydrochloride exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-130705A
CAS No.: 17592-07-3
Purity:  99.68%
Tachysterol 3 is a photoproduct of Previtamin D3 (HY-130705). Previtamin D3 is an orally active, thermolabile steroidal compound that generates vitamin D3, as well as biologically inactive lumisterol and tachysterol. Previtamin D3 is synthesized in the skin of humans and rats via the UV-B-mediated photoconversion of 7-dehydrocholesterol. Previtamin D3 lacks direct anti-rachitic activity, and its in vivo activity relies on the vitamin D3 it produces. Previtamin D3 can be used in studies related to rickets and vitamin D metabolism .
loading...
    loading...
Cat. No.: HY-P99045A
CAS No.: 1796566-95-4

Target:  

ADC Antibodies TROP2

Research Areas:  

Cancer

Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-A0245
CAS No.: 67-96-9
Target:  

VD/VDR

Research Areas:  

Metabolic Disease

Dihydrotachysterol is a synthetic analog of vitamin D. Dihydrotachysterol can be used to for the research of hypocalcemia (lack of calcium in the blood) and hypoparathyroidism (lack of parathyroid hormone in the body) .
loading...
    loading...
Cat. No.: HY-P99010A

Research Areas:  

Cancer

Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
loading...
    loading...
Cat. No.: HY-P99359
CAS No.: 1791416-49-3
Synonyms: ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)

Target:  

TGF-beta/Smad

Research Areas:  

Metabolic Disease

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
loading...
    loading...
Cat. No.: HY-P4666
CAS No.: 13589-07-6
Research Areas:  

Others

Valylhistidine is a dipeptide composed of valine and histidine (Val-His). Valylhistidine can form a dipeptide complex with Cu (II) that mimics superoxide dismutase but lacks activity .
loading...
    loading...
Cat. No.: HY-114672
CAS No.: 150450-53-6
Purity:  99.80%
Research Areas:  

Cardiovascular Disease

MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE .
loading...
    loading...